ORG Wealth Partners LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 301 shares of the medical research company’s stock, valued at approximately $56,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Empirical Finance LLC lifted its holdings in shares of Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after buying an additional 53 shares during the period. American Trust increased its stake in shares of Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 54 shares in the last quarter. OLD National Bancorp IN increased its stake in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares in the last quarter. M&T Bank Corp increased its stake in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its stake in shares of Charles River Laboratories International by 4.5% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 1,842 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $186.07 on Friday. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market cap of $9.51 billion, a PE ratio of 23.29, a P/E/G ratio of 5.00 and a beta of 1.38. The stock has a 50 day moving average price of $193.32 and a 200 day moving average price of $199.71.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the firm earned $2.72 earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price target for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. Robert W. Baird cut their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Evercore ISI lifted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. Finally, Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).